ASP-8731 is under clinical development by Mitobridge and currently in Phase I for Sickle Cell Disease. According to GlobalData, Phase I drugs for Sickle Cell Disease have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASP-8731’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASP-8731 is under development for treatment of sickle cell disease. It is administered through oral route. The drug candidate acts by targeting transcription regulator protein BACH1.
Mitobridge, formerly Mitokyne, a subsidiary of Astellas Pharma Inc is a drug development company. It discovers and develops small molecule therapeutics that recovers mitochondrial functions. The company develops therapies for rare diseases and expands into more common diseases. Mitobridge utilizes screening platform to identify and develop novel therapeutics. In addition, The company holds expertise in the areas of mitochondrial genetic diseases, musculoskeletal, liver disease, kidney, neurodegenerative disorders and diseases and conditions of aging. It works in collaboration with companies in the field of mitochondrial biology and medicine. Mitobridge is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of ASP-8731’s drug-specific PTSR and LoA scores, buy the report here.